TY - JOUR
T1 - Facile Automated Radiosynthesis of an Arginine Selective Bioconjugation Reagent 4‑[18F]Fluorophenylglyoxal for Developing Protein-Based PET Molecular Probes
AU - Sadasivam, Pragalath
AU - Khanapur, Shivashankar
AU - Hartimath, Siddesh V.
AU - Ramasamy, Boominathan
AU - Cheng, Peter
AU - Feng, Chin Zan
AU - Green, David
AU - Goggi, Julian L.
AU - Robins, Edward G.
AU - Yan, Ran
N1 - Publisher Copyright:
© 2025 The Authors. Published by American Chemical Society.
PY - 2025/5/27
Y1 - 2025/5/27
N2 - 4-[18F]Fluorophenylglyoxal ([18F]FPG) is a novel arginine selective bioconjugation reagent for native protein 18F-labeling. Here, we report the automated radiosynthesis of [18F]FPG on a Scintomics GRP module. The radiochemical preparation was performed in a one-pot, two-step process using a DMSO-resistant cassette system. A cartridge-based purification method was developed to purify [18F]FPG without HPLC. The [18F]FPG was prepared in nondecay corrected (n.d.c.) radiochemical yields (RCYs) of 27 ± 2% (n = 5) in 56 min from the end of the bombardment until formulation. The molar activities of [18F]FPG were 147 ± 70 GBq/μmol (n = 5). The 4-[18F]FPG was then conjugated with interleukin-4 (IL-4) in n.d.c. 26 ± 2% RCYs (n = 3) from [18F]FPG with molar activities of 24 ± 4 GBq/μmol (n = 3). [18F]FPG-IL4 exhibited >95% stability in either PBS (4 h) or human serum (2 h) in vitro. [18F]FPG-IL4 showed specific uptake by the PHA-activated Jurkat cells. The in vivo biodistribution and pharmacokinetics of [18F]FPG-IL4 were evaluated in healthy Balb/c mice with PET imaging.
AB - 4-[18F]Fluorophenylglyoxal ([18F]FPG) is a novel arginine selective bioconjugation reagent for native protein 18F-labeling. Here, we report the automated radiosynthesis of [18F]FPG on a Scintomics GRP module. The radiochemical preparation was performed in a one-pot, two-step process using a DMSO-resistant cassette system. A cartridge-based purification method was developed to purify [18F]FPG without HPLC. The [18F]FPG was prepared in nondecay corrected (n.d.c.) radiochemical yields (RCYs) of 27 ± 2% (n = 5) in 56 min from the end of the bombardment until formulation. The molar activities of [18F]FPG were 147 ± 70 GBq/μmol (n = 5). The 4-[18F]FPG was then conjugated with interleukin-4 (IL-4) in n.d.c. 26 ± 2% RCYs (n = 3) from [18F]FPG with molar activities of 24 ± 4 GBq/μmol (n = 3). [18F]FPG-IL4 exhibited >95% stability in either PBS (4 h) or human serum (2 h) in vitro. [18F]FPG-IL4 showed specific uptake by the PHA-activated Jurkat cells. The in vivo biodistribution and pharmacokinetics of [18F]FPG-IL4 were evaluated in healthy Balb/c mice with PET imaging.
UR - https://www.scopus.com/pages/publications/105005080989
U2 - 10.1021/acsomega.5c01278
DO - 10.1021/acsomega.5c01278
M3 - Article
AN - SCOPUS:105005080989
SN - 2470-1343
VL - 10
SP - 20570
EP - 20577
JO - ACS Omega
JF - ACS Omega
IS - 20
ER -